Eckol, a potential inhibitor of aryl hydrocarbon receptor, inhibits proliferation and induces apoptosis in breast cancer cells.
Eckol, a potential inhibitor of aryl hydrocarbon receptor, inhibits proliferation and induces apoptosis in breast cancer cells

Pelin Balcik-Ercin

Department of Biology, Faculty of Science, Dokuz Eylul University, Izmir 35390, Turkey.

Abstract

The present study was designed to explore phlorotannin eckol protein targets and evaluate the anti-cancer effects of eckol against human breast cancer cells. ProTox-II server and protein-ligand docking analysis determined the aryl hydrocarbon receptor (AhR) as a putative target of eckol. The AhR has been determined as a potential target for breast cancer treatment. The effect of eckol treatment on proliferation, apoptosis, and cell cycle activities was detected in MDA-MB-231 and SK-BR-3 breast cancer cell lines which were selected dependent on AhR expression profiles. Consistent with the AhR expression profile, MDA-MB-231 cells were more sensitive to eckol treatment compared to SK-BR-3 cells in proliferation, apoptosis and cell cycle results. Eckol treatment shows a significant antiproliferative and apoptotic response in breast cancer cells. Overall, these results indicated that the action of eckol may be related to the AhR gene regulation in different breast cancer cell lines.

Introduction

Breast cancer is the most common cancer type in female populations and the second cancer-related death worldwide (Bray et al., 2018). Several chemotherapeutic agents and their combinations are used for breast cancer treatments and their cytotoxic roles on breast cancer cell line models were detailed and described (Waks and Winer, 2019). Although molecular characterization and treatment options for breast cancer are well known, it still is the leading cause of cancer-related death in females (Cardoso et al., 2017). Therefore, there is an urgent need to identify and characterize novel molecules associated with cancer malignancy for breast cancer therapy.

Among the different types of bioactive phlorotannins, one of the essential metabolites is eckol (Zhang et al., 2012). The bioactivities of eckol-type phlorotannins can be classified as antioxidant, anti-diabetic, hepatoprotective, neuroprotective, radioprotective, anti-aging, anti-hypertensive, anti-inflammatory, anti-obesity, antihistaminic, anti-inflammatory, antihyperlipidemic, antityro-

This work is licensed under a Creative Commons Attribution 4.0 License. You are free to copy, distribute and perform the work. You must attribute the work in the manner specified by the author or licensor.
sinase, anti-cancer, and cytotoxic (Manandhar et al., 2019). The broad variety of these activities put forward eckol as a highly potential therapeutic agent. Eckol is a phlorotannin isolated from a brown alga Ecklonia cava.

Eckol anti-cancer activity has been determined in limited studies, such as human HeLa (cervical), SW1990 (pancreatic), HepG2 (hepatocellular), and MCF7 (breast) cancer cells (Jun et al., 2014; Mwangi et al., 2017; Zhang et al., 2019). A recent study showed that eckol has anti-tumor activity in xenograft-bearing mice model by immunomodulatory activity (Zhang et al., 2019). Studies have shown that eckol is a very effective compound in various human cancer cell models. However, only limited data have been described in the literature explaining the mechanism of eckol related to its anti-cancer activity.

The present study aims to identify possible targets of eckol and the role of the eckol on proliferation, apoptosis, and cell cycle processes in different breast cancer cell lines.

Materials and Methods

Cell culture

The breast cancer cell lines MDA-MB-231 and SK-BR-3 were maintained in high-glucose (4.5 g/L) DMEM media, containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% non-essential amino acids.

Cell proliferation assay and eckol concentration determination

The antiproliferative effects of eckol (Kozak et al., 2020) on MDA-MB-231 and SK-BR-3 cells were determined by the xCELLigence system which measures real-time cell impedance. The special biosensor plates (E-plate) are compatible with the system and the plates measure target cell adhesion and growth (Picot et al., 2017). The control cells were treated with 0.05% final concentration of DMSO same as Eckol.

Step 1: Add 100 µL cell media in each well
Step 2: Background reading

Step 3: Cells were plated in 16-well plate at an initial density of 5 x 10^4 cells, with 50 µL media per well
Step 4: After 24 hours of incubation check the cell proliferation
Step 5: Eight different concentrations of 50 µL eckol (Control, 20, 40, 80, 160, 320, 400, and 480 µM) were added to each well
Step 6: Cell indexes values obtained through the software

Reference

Picot et al. 2017
and ANOVA test. A p value of <0.05 was considered statistically significant. All experiments were performed in triplicate.

### Results

**Eckol target identification and selection of breast cancer cell lines**

To investigate the effect of eckol in breast cancer, the possible targets of the eckol were tested by the toxicity chemicals database. In the target analysis result, MMP and AhR were identified as active targets of eckol and the AhR has a high probability rate (0.76) (Table I).

The toxicity chemicals database results prompted us to perform molecular docking studies to understand the eckol-AhR (ligand-protein) interactions by Autodock Vina 1.1.2 (Seeliger and de Groot, 2010). The accommodation of eckol revealed various amino acid residues engaged in interaction. These interactions were attributed to evidence of the *in silico* ligand-protein interaction. Eckol showed a prominent interaction with the AhR protein accompanied by an affinity of −8.5 kcal/mol and one hydrogen bond specifically with MET237 and seven pi-alkyl interactions with ALA267, LEU224, VAL158, and VAL129. The eckol displayed binding in the helix and beta-strands (PAS-A domain with VAL129 and VAL158) of the AhR protein (Figure 1).

After determining that eckol interacted with AhR protein with a high energy level, the breast cancer cell lines were selected according to their AhR gene expression profile. The three breast cancer cell lines, luminal MCF-7, triple-negative MDA-MB-213, and HER2 enrich SK-BR-3, were interesting for expression profile analysis determined by the expression database. AhR expression was the highest in MDA-MB-231, med-ium in MCF-7, and the lowest in SK-BR-3 detected as17 FKPM, 10 FKPM, and 5FKPM respectively (Figure 2).

**Effect of eckol on breast cancer cell lines proliferation**

After the selection of the AhR the highest expressed MDA-MB-213 and lowest expressed cell lines SK-BR-3, we tested the role of eckol in cell proliferation. Cells were treated at 0, 20 µM, 40 µM, 80 µM, 160 µM, 400 µM, and 480 µM eckol for 2, 4, 6, and 8 hours. The MDA-MB-213 cell proliferation was significantly inhibited on 320 µM eckol concentration after 2 hours of treatment (77.6%) and 480 µM eckol concentration inhibited proliferation ~50% (2 hours 47.7%, 4 hours 48%, 6 hours 47.2%, and 8 hours 45.9%) in all-time analyses (Figure 3A). The SK-BR-3 proliferation was significantly ~20% (2 hours 84.2%, 4 hours 83.8%, 6 hours 81.4% and 8 hours 81.5%) decreased after 480 µM eckol treatment in all-time analysis (Figure 3B). As a result, compatible with the AhR gene expression profile, the triple-negative MDA-MB-213 breast cancer cells which have high AhR gene expression, were more sensitive to eckol treatments at high concentrations compared to SK-BR-3 cells (480 µM).

**Effect of eckol on apoptosis in breast cancer cell lines**

After the determination of the cell proliferation role of eckol on breast cancer cell models, we assessed whether the observed cellular growth inhibition by eckol treatment was accompanied by apoptotic death in two

<table>
<thead>
<tr>
<th>Target</th>
<th>Prediction</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatotoxicity</td>
<td>Inactive</td>
<td>0.78</td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>Inactive</td>
<td>0.64</td>
</tr>
<tr>
<td>Immunoxicity</td>
<td>Inactive</td>
<td>0.93</td>
</tr>
<tr>
<td>Mutagenicity</td>
<td>Inactive</td>
<td>0.55</td>
</tr>
<tr>
<td>Cytotoxicity</td>
<td>Inactive</td>
<td>0.91</td>
</tr>
<tr>
<td>Aryl hydrocarbon receptor (AhR)</td>
<td>Active</td>
<td>0.76</td>
</tr>
<tr>
<td>Androgen receptor (AR)</td>
<td>Inactive</td>
<td>0.97</td>
</tr>
<tr>
<td>Androgen receptor ligand binding domain (AR-LBD)</td>
<td>Inactive</td>
<td>0.90</td>
</tr>
<tr>
<td>Aromatase</td>
<td>Inactive</td>
<td>0.67</td>
</tr>
<tr>
<td>Estrogen receptor alpha (ER)</td>
<td>Inactive</td>
<td>0.50</td>
</tr>
<tr>
<td>Estrogen receptor ligand binding domain (ER-LBD)</td>
<td>Inactive</td>
<td>0.62</td>
</tr>
<tr>
<td>Peroxisome proliferator-activated receptor gamma (PPAR-gamma)</td>
<td>Inactive</td>
<td>0.96</td>
</tr>
<tr>
<td>Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE)</td>
<td>Inactive</td>
<td>0.86</td>
</tr>
<tr>
<td>Heat shock factor response element (HSE)</td>
<td>Inactive</td>
<td>0.86</td>
</tr>
<tr>
<td>Mitochondrial membrane potential (MMP)</td>
<td>Active</td>
<td>0.64</td>
</tr>
<tr>
<td>Phosphoprotein (tumor suppressor) p53</td>
<td>Inactive</td>
<td>0.84</td>
</tr>
<tr>
<td>ATPase family AAA domain-containing protein 5 (ATAD5)</td>
<td>Inactive</td>
<td>0.85</td>
</tr>
</tbody>
</table>
different concentrations in two cell lines to a minimum time manner (2 hours). We selected 160 µM which did not significantly affect cell line proliferation and 480 µM concentrations which significantly affected proliferation on both cell lines conversely. Following treatment with 160 µM of eckol, the percentage of early apoptotic cells was significantly different on treated compared to untreated MDA-MB-231 cells (6.0 ± 0.3% vs 0.1 ± 0.0% in controls; Figure 4A), at 2 hours of treatment. After 2 hours of treatment with 480 µM eckol, MDA-MB-231 cells displayed significantly higher levels of apoptosis compared to untreated cells, totally in over half of MDA-MB-231 cells were apoptotic; early apoptosis was 0.1% in control vs 8.2% in 480 µM eckol treated and late apoptosis 1.7% in control vs 50.6% in 480 µM eckol treated, respectively (Figure 4A). SK-BR-3 cells were treated with 160 µM for 2 hours and the apoptotic cell rate did not significantly change early apoptotic cell rate (2% in 160 µM eckol treated vs. 1.6% in controls). In a dose-dependent manner, SK-BR-3 cell responses were changed and the late apoptotic cell rate was significantly increased at 480 µM compared to control cells, 19.4% and 4.8%, respectively (Figure 4B). The proliferation results were consistent with the apoptosis data, suggesting that eckol treatment more effectively inhibits proliferation and also caused nearly 60% of the cells to apoptotic in MDA-MB-231 cells, which is a high AhR expressed cell line.

Effect of eckol on cell cycle progression

Given our data on the effect of eckol on the inhibition of cellular growth and apoptosis, we tested the effect of eckol at a concentration of 160 µM and 480 µM on cell cycle progression at 2 hours of treatment on MDA-MB-231 and SK-BR-3 cell lines. As shown in Figure 5A, 2 hours of 160 µM eckol treatment resulted in significant cell cycle arrest at the G1 phase (58.5% vs 46.1% in controls) and 480 µM treatment caused G2/M arrest in MDA-MB-231 cells (60.1% vs. 24.7% in controls). G1 arrest was not detected after 160 (57.9%) and 480 µM (55.9%) eckol treatment in SK-BR-3 cells (56.4% in controls). G2/M phase cell amount was increased at
480 µM (21.1%) compared to 160 µM (15.8%) but cells did not significantly arrest compared to control (19.9% in controls) (Figure 5B). Cell cycle responses to eckol treatment were similar to proliferation and apoptosis responses in MDA-MB-231 cells, on the contrary, SK-BR-3 cells cell cycle progression rate was not significantly changed after eckol treatment.

Discussion

Humans have long used naturally occurring substances for medical purposes. Plants, in particular, have played a leading medical role in most cultures (Dyshlovoy and Honecker, 2015). Cancer is the second leading cause of death in the world and breast cancer is the first cause of mortality in the female population. Breast cancer is a complex and heterogeneous disease and is well-characterized according to molecular profile (Yersal and Barutca, 2014). Breast cancer is modeled by cell lines according to molecular classification and cell lines have been widely used for anti-cancer drug studies. For breast cancer treatment, multiple chemotherapeutic drugs use, such as doxorubicin, paclitaxel, cisplatin, 5-fluorouracil, and these drugs target proliferative cells without cancer cell-specific molecular targeting (Fisusi and Akala, 2019). Although breast cancer is a well-determined cancer type, still research work on new therapeutic strategies for breast cancer cure.

The anti-cancer effect of purified phlorotannin eckol has been determined on various cancer cell lines including breast cancer cell line MCF-7 (Jun et al., 2014; Mwangi et al., 2017; Zhang et al., 2019). However, the target of eckol has not been identified yet. For this purpose, first, we detected molecular target of the eckol in the Prototx II database. Database results showed us that AhR is a possible target of eckol with a high probability rate. The AhR protein, a basic helix-loop-helix/per-arin-sim (bHLH/PAS) family member, is a ligand-activated
transcription factor that is an essential regulator of a broad spectrum of biological activities. The binding of a ligand to AhR generates conformational changes and AhR translocates to the nucleus. AhR dimerizes with its partner protein AhR nuclear translocator (ARNT) and the PAS-A domain dictates AHR–ARNT dimerization and complex binds to xenobiotic-responsive elements (XREs) in the regulatory region of target genes, inducing their transcription (Paris et al., 2021). The overexpression of AhR mRNA levels were detected in many cancers, including breast, lung, thyroid, and oral squamous cell carcinoma (Su et al., 2013; Li et al., 2014; Stanford et al., 2016; Vacher et al., 2018; Moretti et al., 2020). The previous study pointed out that the AhR is a potential target for breast cancer therapy (Powell et al., 2013).

Next, we analyzed eckol-AhR interaction with protein docking analysis. The in silico docking result revealed that eckol binds the AhR protein and this binding include the PAS-A domain which is essential for the dimerization of AhR protein (Corrada et al., 2016).

Concerning that results, we decided to research the role of eckol on breast cancer cells according to the AhR expression profile. According to the European Bioinformatics Institute database (ebi. ac. the UK), results, triple-negative breast cancer cell line MDA-MB-231 cells expressed higher levels of AhR than SK-BR-3 HER2 enriched cells. These results were compatible with previous data that showed the AhR expression profile in breast cancer cell lines (Gilbert et al., 2018).

The AhR is a ligand-activated transcription factor and mediates the effects of a large class of polycyclic and polyhalogenated aromatic hydrocarbons pollutants on cellular toxicity. Furthermore, recent studies pointed out that AhR has cellular functions including proliferation, cell cycle, pluripotency, and stemness (Baker et al., 2019). Interestingly, the cellular functions of AhR match the hallmarks, and new studies showed that AhR overexpression is important for breast cancer and AhR is a remarkable drug target candidate for breast cancer cure (Vacher et al., 2018; Mohamed et al., 2019). Identification of eckol target AhR and the importance of AhR in breast cancer prompted us to analyze eckol role in the proliferation of breast cancer cell lines dependent on AhR expression profile. We treated cells with various concentrations and times with eckol and eckol has antiproliferative effect in both breast cancer cell lines. Interestingly the responses of the MDA-MB-231 cell line were more sensitive to eckol treatment compared to the SK-BR-3 cell line. Although low AhR expressed cell line SK-BR-3 proliferation was decreased ~20 percent, high AhR expressed cell line MDA-MB-231 cell line proliferation was decreased ~50% after eckol treatment.

In this apoptosis analysis, we found that in response to the 160 µM concentration of eckol treatment MDA-MB-231 cells had significantly higher rates of early apop-
tosis than controls but apoptotic response of SK-BR-3 cells to eckol treatment was similar to control conditions. In a dose-dependent manner, MDA-MB-231 cells apoptotic rate was over half percent after 480 µM eckol treatment. On the contrary, eckol has a protective role against apoptosis, such as lethal radiation or oxidative stress (Zhang et al., 2008; Piao et al., 2012). Only limited data is available about the effect of eckol on the cell cycle. After eckol treatment, pancreatic cancer cells accumulated in the sub-G1 phase in the cell cycle (Zhang et al., 2019). Our analysis demonstrated that cell cycle progression changed in a dose-dependent manner; we observed an accumulation of cells in the G2/M phase in MDA-MB-231 cells. On the contrary, SK-BR-3 cell cycle progression did not change significantly after the eckol treatment compared to untreated cells.

Conclusion
The present results suggest that eckol interacts with AhR protein and there are eckol response differences associated with AhR gene expression in breast cancer subtypes.

Financial Support
Self-funded

Conflict of Interest
Author declares no conflict of interest

Acknowledgement
I would like to thank Dilek Unal and Inci Tuney Kızılkaya for eckol reagent.

References


